Creatine HCl Peri/Menopause RCT — 8 Weeks Improves Cognition·Mood·Brain ATP. 1,500mg/day Optimal

A non-prescription dietary option for the peri/menopausal “brain fog·mood swing·sarcopenia” triangle has now been validated in an RCT. The CONCRET-MENOPA (Creatine in Menopausal Women) trial published in Journal of the American Nutrition Association 2026 — 36 peri/menopausal women received creatine HCl 1,500mg/day for 8 weeks, achieving meaningful improvements in reaction time + frontal creatine concentration + mood swings. The 800mg HCl + ethyl ester combo provided additional anxiety relief·alertness benefit. Zero side effects.

How Perimenopause Affects Brain·Muscle

Perimenopause (menopause transition, average ages 45~55) is the period of greatest estrogen fluctuation. This fluctuation directly impacts the following circuits:

Brain circuit:

• Estrogen directly regulates brain ATP production (mitochondria)
• Perimenopause ATP production ↓ → brain energy deficit
• Result: brain fog (cognitive slowing), word recall decline, ↓ concentration

Muscle circuit:

• Estrogen stimulates muscle protein synthesis
• Perimenopause sarcopenia accelerates
• Bone density ↓ + muscle strength ↓ + fall risk ↑

Mood circuit:

• Estrogen stabilizes serotonin·dopamine systems
• Perimenopause mood swings·depression·anxiety frequency ↑
• Hormone fluctuation period depression prevalence 1.5~3x

Why Creatine Is the Target

Creatine is central to muscle·brain ATP recovery:

1. Muscle:

• Muscle fiber ATP resynthesis → exercise capacity ↑
• Increased muscle water retention → muscle volume ↑
• Combined with exercise prevents sarcopenia (proven)

2. Brain:

• Brain creatine concentration (frontal·hippocampal) ↑ → cognitive ATP recovery ↑
• Neuroprotection (reactive oxygen ↓)
• Some RCTs report depression·anxiety adjunct effects

3. Perimenopause specificity:

• Compensates for ATP production decline from estrogen reduction
• Diet alone insufficient → supplementation needed

CONCRET-MENOPA Study Design

Subjects: 36 peri/menopausal women, average age 50.1±5.7

4-arm randomized 8-week RCT:

Arm	Dose	Form
Placebo	-	-
Low-dose HCl	750mg/day	HCl
Mid-dose HCl	1,500mg/day	HCl
Combo	800mg/day	HCl + ethyl ester

Measurements:

• Cognition: reaction time, working memory, attention (Stroop·n-back)
• Brain imaging: 1H-MRS (frontal creatine concentration)
• Mood·QoL: POMS (Profile of Mood States), MENQOL (menopause symptoms)
• Safety: liver·kidney function, side effects

Key Results

1. 1,500mg/day HCl superior:

• Reaction time improved vs placebo (p<0.05)
• Frontal creatine concentration ↑
• Mood swings (anger·depression) reduced
• Physical fatigue reduced

2. 800mg combo (HCl+ethyl ester):

• Anxiety scores ↓
• Alertness ↑
• Some working memory improvement

3. 750mg low dose:

• Partial effect only, statistical significance lacking

4. Safety:

• Zero side effects across all 4 arms
• Liver·kidney function maintained normal
• No major weight·body water changes

Difference from Standard Creatine Monohydrate

Creatine monohydrate (most common form):

• Proven efficacy, low cost
• 5g/day standard dose
• Some GI discomfort (gas·bloating)
• Variable absorption
• Water retention (1~2 kg ↑ body weight)

Creatine HCl:

• Higher absorption than monohydrate
• 1,5003,000mg/day sufficient (1/31/2 dose)
• ↓ GI discomfort
• More expensive
• Less body water increase (↓ weight change)

Why HCl form is preferred in perimenopausal women — ↓ GI burden + ↓ body water increase (sensitive to edema during this period).

8-Week Protocol

Initiation:

• HCl 1,500mg/day with food (single or split dose)
• Pre or post exercise unrelated (unlike monohydrate, no loading needed)

Recommended adjuncts:

• Resistance exercise 2~3x/week
• Protein 1.2~1.6 g/kg/day
• Adequate water (1.5~2 L/day)
• Vitamin D 2,000 IU/day

Evaluation:

• 4-week mark: subjective change (concentration·mood)
• 8-week mark: reaction time·strength measurements
• 12 weeks: effect consolidation + long-term use decision

Natural Matrix — Integrated Perimenopause Management

Creatine isn’t standalone but part of a matrix:

Diet:

• Protein (meat·fish·egg — natural creatine sources)
• Omega-3 EPA/DHA 1~2 g/day (inflammation·brain protection)
• Magnesium 300~400 mg/day (muscle·sleep)
• Vitamin D 30~50 ng/mL maintenance

Exercise:

• Resistance exercise 2~3x/week (essential)
• Aerobic 150+ min/week moderate intensity
• Balance·flexibility (yoga·pilates)

Sleep·stress:

• 7~9 hours sleep (recovery·memory consolidation)
• Chronic stress management (cortisol drives sarcopenia·brain ATP slowing)
• Meditation·breathwork (autonomic balance)

Drug Matrix — Complementary Options

Creatine supplementation + the following drug options integrate:

Hormone replacement therapy (MHT):

• Estrogen + progesterone
• Consult physician at perimenopause onset
• Simultaneous cognition·muscle·mood effects

Others:

• Melatonin for menopause sleep disturbance
• SSRI (low-dose) or fenazapamine for hot flashes
• Calcium·vitamin D + romosozumab·denosumab for bone density loss

Korean Clinical Significance

Korean perimenopause statistics:

• Average menopause age 49.7
• Perimenopause start average age 45
• 4050% report meaningful symptoms

Korean creatine supplement accessibility:

• Monohydrate common as fitness supplement
• HCl form is premium line (pharmacies·online)
• Price: monohydrate ₩10,00020,000/month / HCl ₩30,00050,000/month

Conclusion

Creatine HCl is settling as a non-prescription dietary option for the perimenopausal cognition·muscle·mood triangle. The CONCRET-MENOPA RCT validated 1,500mg/day efficacy at 8 weeks. A supplementation tool within the exercise·protein·sleep·stress management matrix. A safe primary option applicable before or alongside hormone replacement therapy decisions. Settling as a new standard in menopause precision nutrition.